Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial

Published:2022-04-13 Issue:6 Volume:39 Page:3011-3018
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Dreher Michael,Grohè Christian,Hartmann Niels-Ulrik,Kanzler Stephan,Kraft Karin,Sarrazin Christoph,Doll Michael,Spiesshöfer Jens,Steiner Stephan,Wöhrle Jochen,Seeger Julia,Röschmann-Doose Kristina,Thomsen Jörn,Wittig Thomas,Marx Nikolaus,Eisenmann Stephan

Funder

Universitätsklinikum RWTH Aachen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02135-z.pdf

Reference19 articles.

1. Robinot R, Hubert M, Dias de Melo G, et al. SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance. Nat Commun. 2021;12:1–16.

2. Wittig T. Mucociliary clearance in COVID-19-an underestimated danger area in early phase of disease? MMW Fortschr Med. 2021;163:21–7.

3. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. Br Med J. 2021;374. https://doi.org/10.1136/bmj.n1648.

4. Mandal S, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396–8.

5. Fürst R, Luong B, Thomsen J, Wittig T. ELOM-080 as add-on treatment for respiratory tract diseases—a review of clinical studies conducted in China. Planta Med. 2019;85:745–54.